Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Current Deferred Revenue (2020 - 2026)

NeuroPace has reported Current Deferred Revenue over the past 5 years, most recently at $100000.0 for Q1 2026.

  • For Q1 2026, Current Deferred Revenue fell 85.71% year-over-year to $100000.0; the TTM value through Mar 2026 reached $100000.0, down 85.71%, while the annual FY2025 figure was $100000.0, 83.33% down from the prior year.
  • Current Deferred Revenue for Q1 2026 was $100000.0 at NeuroPace, roughly flat from $100000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $1.1 million in Q4 2023 and troughed at $100000.0 in Q4 2025.
  • A 4-year average of $625500.0 and a median of $698000.0 in 2024 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: decreased 13.0% in 2025 and later tumbled 85.71% in 2026.
  • Year by year, Current Deferred Revenue stood at $1.1 million in 2023, then tumbled by 44.95% to $600000.0 in 2024, then tumbled by 83.33% to $100000.0 in 2025, then changed by 0.0% to $100000.0 in 2026.
  • Business Quant data shows Current Deferred Revenue for NPCE at $100000.0 in Q1 2026, $100000.0 in Q4 2025, and $600000.0 in Q3 2025.